The 2026 Biologics Wave: Which Innovations Will Break Through? Contract Pharma FDA Category 2 Update: The 5 Peptides Still Facing Heavy Review As excitement builds around peptides potentially moving off the FDA Category 2 list, it's important to understand one key reality: Not FDA's Overreach on Compounded Peptides FDA IS REPORTEDLY EXPECTED TO LIFT RESTRICTION ON PEPTIDES NYT FDA User Fees for FY 2026 Alba